Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxymorphone is a potent opioid analgesic used for the management of moderate to severe pain, particularly in patients who require an opioid and for whom alternative treatments are inadequate. It is available as immediate-release and extended-release oral tablets, as well as injectable formulations. Oxymorphone acts primarily as a selective agonist at the mu-opioid receptor in the central nervous system, altering pain perception and response. At higher doses, it may interact with other opioid receptors. The drug is more lipophilic than morphine, allowing easier penetration of the blood-brain barrier. Oxymorphone has no significant interactions with major cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2D6), reducing its potential for certain drug-drug interactions[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxymorphone.